Polyplus in vivo Consortium
Join and meet leaders in the field!
- Discuss your experiments and share knowledge with your fellow scientists and clinicians
- Benefit from our expertise and support when organizing pre-clinical studies and clinical trials
The Polyplus in vivo Consortium has been established to bring together researchers, scientists and clinicians to facilitate the development of therapy programmes using genes or oligonucleotides delivered using non-viral tools developed by Polyplus-transfection. The Polyplus in vivo Consortium is a collaborative group of academic and corporate research scientists and hence an exciting place to discuss therapeutic projects and delivery issues with others as well as regulatory considerations. The Polyplus in vivo Consortium will enable the research groups working on therapeutic projects involving nucleic acid delivery to share their expertise in order to significantly accelerate their clinical research and the development of therapeutics.
Past Meetings
November 22-23, 2007 in Paris, France
November 27-28, 2008 in Paris, France
December 10-11, 2009 in Paris, France
Download the Polyplus in vivo Consortium file (812 ko)
More information:
Criteria for joining the ConsortiumThe Polyplus in vivo Consortium is open to any research group that wishes to use Polyplus in vivo non-viral delivery technology to develop therapeutic applications using nucleic acids. Among Polyplus’ reagents, in vivo-jetPEI™ is one of the most potent non-viral reagents and is now available for clinical trials. Members are expected to share and discuss part of their knowledge and expertise as a central part of the Consortium’s mission.
As the initiator and coordinator of the Consortium, Polyplus-transfection is committed to providing technical expertise and know-how to members wishing to develop in vivo delivery experiments with Polyplus products. Moreover, Polyplus is committed to coordinating the network and to organizing meetings for members.
Polyplus-transfection will provide:
- extensive technical support and will share its expertise and research data regarding in vivo delivery
- advice for your pre-clinical experiments
- active support to customers preparing application files for clinical trials (IND)
Members of the Polyplus in vivo Consortium will receive:
- preferential prices for Polyplus in vivo clinical grade transfection reagents
- priority access to Polyplus scientific experts
- expertise and support when organizing pre-clinical studies and clinical trials
We expect the Consortium to expand nucleic acids-based therapeutics using non-viral delivery reagents by accelerating the transfer from pre-clinical studies to clinical trials.
To obtain more information about the Polyplus in vivo Consortium or to join the Consortium, please contact:
Pascale Belguise
Business Development Manager
